FDA proposes to withdraw Amgen drug for rare autoimmune diseases over effectiveness concerns.
The FDA is proposing to withdraw Amgen's drug for rare autoimmune diseases due to effectiveness concerns.
What happened
The FDA is proposing to withdraw Amgen's drug for rare autoimmune diseases due to effectiveness concerns.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near United States
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
Over 280 million people (3% of the world) live with chronic hepatitis B and C, WHO says in new 2026 Global Hepatitis Report.
Over 280 million people, approximately 3% of the global population, were living with chronic hepatitis B and C as of 2024, according to the new WHO 2026 Global Hepatitis Report.
President Donald Trump is unlikely to accept Iran's latest proposal for conflict resolution, as reports indicate the plan fails to address key concerns regarding the nation's nuclear program.
President Donald Trump is unlikely to accept Iran's latest proposal for conflict resolution, as CNN reports the plan leaves questions regarding the country's nuclear program unresolved.
Two Spirit Airlines creditors are backing a bailout plan proposed by President Trump, the Financial Times reports.
Two creditors of Spirit Airlines have expressed support for a bailout plan proposed by President Trump, according to the Financial Times.
Google secures a classified AI contract with the Pentagon, according to a report from The Information. The deal moves forward despite internal pushback from company employees regarding the partnership.
Google has secured a classified artificial intelligence contract with the U.S. Department of Defense, according to a report from The Information, despite internal opposition from company employees.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.